{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:48:48Z","timestamp":1786114128304,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA197731"],"award-info":[{"award-number":["R35CA197731"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116255","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:58:13Z","timestamp":1770134293000},"page":"116255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer"],"prefix":"10.1016","volume":"236","author":[{"given":"Deblina","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslamuzzaman","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh Kumar Kantilal","family":"Vasiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Vudatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-1407","authenticated-orcid":false,"given":"Nicolas","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Iacobuzio-Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Trevino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said M.","family":"Sebti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116255_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116255_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biom14030364","article-title":"A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present","volume":"14","author":"Bestari","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejca.2026.116255_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-021-02478-x","article-title":"Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution","volume":"20","author":"Li","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116255_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116255_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116255_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2026.116255_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116255_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116255_bib9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2026.116255_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116255_bib11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116255_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116255_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116255_bib14","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116255_bib15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116255_bib16","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRAS(G12C) Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116255_bib17","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS(G12C) Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116255_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116255_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2021.10.003","article-title":"HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2","volume":"159","author":"Ho","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116255_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116255_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160141","article-title":"Direct GDP-KRAS(G12C) inhibitors and mechanisms of resistance: the tip of the iceberg","volume":"15","author":"Rosen","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.116255_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2026.116255_bib23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations","volume":"9","author":"Zeissig","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2026.116255_bib24","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2026.116255_bib25","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116255_bib26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116255_bib27","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116255_bib28","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","article-title":"Feedback activation of EGFR\/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer","volume":"42","author":"Feng","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2026.116255_bib29","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","article-title":"Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma","volume":"83","author":"Gulay","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116255_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.244.915720","article-title":"Concurrent inhibition of EGFR and KRAS synergistically suppresses cell growth and prevents ERK reactivation in KRAS<sup>G12D<\/sup>-mutant PDAC","volume":"389","author":"Amparo","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2026.116255_bib31","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.21873\/anticanres.16629","article-title":"Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS(G12D) Inhibitor, in Colorectal Cancer Treatment","volume":"43","author":"Kataoka","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2026.116255_bib32","article-title":"Pharmacologically targeting KRAS (G12D) in PDAC models: tumor cell intrinsic and extrinsic impact","author":"Kumarasamy","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejca.2026.116255_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216904","article-title":"Site-specific mutagenesis screening in KRAS(G12D) mutant library to uncover resistance mechanisms to KRAS(G12D) inhibitors","volume":"591","author":"Choi","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2026.116255_bib34","article-title":"Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2","author":"Miyazaki","year":"2024","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2026.116255_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk0850","article-title":"Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejca.2026.116255_bib36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc3151","article-title":"Targeting protein prenylation for cancer therapy","volume":"11","author":"Berndt","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116255_bib37","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-18-3399","article-title":"Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors","volume":"25","author":"Kazi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116255_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0092-8674(91)90460-G","article-title":"Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit","volume":"65","author":"Seabra","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116255_bib39","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1016\/S0021-9258(17)41845-X","article-title":"cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I","volume":"269","author":"Zhang","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116255_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ejca.2026.116255_bib41","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2026.116255_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106082","article-title":"Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers","volume":"26","author":"Tyc","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ejca.2026.116255_bib43","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1158\/1078-0432.CCR-10-2544","article-title":"Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice","volume":"17","author":"Balasis","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116255_bib44","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.leukres.2013.07.034","article-title":"Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies","volume":"37","author":"Sampath","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2026.116255_bib45","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/2767-9764.CRC-23-0222","article-title":"Discovery of KRB-456, a KRAS G12D Switch-I\/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors","volume":"3","author":"Kazi","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ejca.2026.116255_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112570","article-title":"Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF\/MEK inhibition in melanoma","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2026.116255_bib47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116255_bib48","first-page":"4115","article-title":"The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma","volume":"7","author":"Tascilar","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116255_bib49","doi-asserted-by":"crossref","first-page":"16704","DOI":"10.18632\/oncotarget.14335","article-title":"Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116255_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9124019","article-title":"CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study","volume":"9","author":"Lin","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2026.116255_bib51","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3390\/cimb46040177","article-title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer","volume":"46","author":"Stefanoudakis","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.ejca.2026.116255_bib52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jtho.2024.11.022","article-title":"FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer","volume":"20","author":"Kazi","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:25:52Z","timestamp":1785961552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"alternative-id":["S0959804926000353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116255","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116255"}}